12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MGAH22: Phase I started

MacroGenics began an open-label, dose-escalation, U.S. and Korean Phase I trial in about 36 patients to evaluate weekly 0.1-15 mg/kg...

Read the full 80 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >